Clinical trial
Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia…
NCT00412243 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00412243 |
|---|---|
| Title | Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients |
| Official title | Phase I/II Study of Clofarabine Plus Cyclophosphamide for Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Genzyme, a Sanofi Company Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Burkitt's Lymphoma, Lymphoblastic Lymphoma, Acute Lymphoblastic Leukemia |
| Intervention type | Drug |
| Interventions | Clofarabine, Cyclophosphamide |
| Enrollment | 51 |
| Start date | Mar 1, 2006 |
| Primary completion | Apr 1, 2012 |
| Completion | Apr 1, 2012 |
| First posted | Dec 18, 2006 |
| Last update posted | Mar 12, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: